Literature DB >> 9317162

TGF-beta production regulates the development of the 2,4,6-trinitrophenol-conjugated keyhole limpet hemocyanin-induced colonic inflammation in IL-2-deficient mice.

B R Lúdvíksson1, R O Ehrhardt, W Strober.   

Abstract

A severe, Th1-mediated experimental colitis with similarities to inflammatory bowel disease in humans can be induced by a single injection of 2,4,6-trinitrophenol (TNP)-substituted protein plus adjuvant in IL-2-/- mice. To determine the early events involved in the pathogenesis of IL-2-/-colitis, we compared the function of lamina propria (LP) T cells from IL-2-/- and IL-2+/+ mice subjected to disease-inducing (TNP-conjugated keyhole limpet hemocyanin [TNP-KLH]) and disease-inhibiting (anti-CD3) immunization protocols. We show that LP T cells in TNP-KLH-immunized IL-2-/- mice fail to produce TGF-beta early (day 2), whereas LP T cells in TNP-KLH-immunized IL-2+/+ mice exhibit an approximately eightfold rise in TGF-beta secretion. The critical importance of local TGF-beta production was further substantiated by the following findings. 1) LP T cells from TNP-KLH-immunized IL-2-/- mice administered anti-CD3 (i.p.) exhibit a significant rise in TGF-beta, production but fail to produce IFN-gamma, and such mice do not develop colitis. 2) TNP-KLH-immunized IL-2-/- mice administered anti-CD3 and coadministered anti-TGF-beta mAb again give rise to IFN-gamma-producing LP cells, and such mice develop colitis. 3) TNP-KLH-immunized IL-2+/+ mice administered anti-TGF-beta mAb exhibit pockets of mononuclear cell infiltrates in the LP. These results indicate that the disposition of IL-2-/- mice to develop chronic colonic inflammation is due to a Th1 cell response in the LP that is not appropriately counter-regulated by the production of the suppressor cytokine, TGF-beta.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9317162

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

1.  Transforming growth factor beta1 is expressed in the jejunum after experimental Cryptosporidium parvum infection in humans.

Authors:  P Robinson; P C Okhuysen; C L Chappell; D E Lewis; I Shahab; S Lahoti; A C White
Journal:  Infect Immun       Date:  2000-09       Impact factor: 3.441

2.  TGF-beta/Smad signaling defects in inflammatory bowel disease: mechanisms and possible novel therapies for chronic inflammation.

Authors:  C Fiocchi
Journal:  J Clin Invest       Date:  2001-08       Impact factor: 14.808

Review 3.  Oral tolerance.

Authors:  W Strober; B Kelsall; T Marth
Journal:  J Clin Immunol       Date:  1998-01       Impact factor: 8.317

4.  Microflora reactive IL-10 producing regulatory T cells are present in the colon of IL-2 deficient mice but lack efficacious inhibition of IFN-gamma and TNF-alpha production.

Authors:  M Waidmann; Y Allemand; J Lehmann; S di Genaro; N Bücheler; A Hamann; I B Autenrieth
Journal:  Gut       Date:  2002-02       Impact factor: 23.059

5.  Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease.

Authors:  G Monteleone; A Kumberova; N M Croft; C McKenzie; H W Steer; T T MacDonald
Journal:  J Clin Invest       Date:  2001-08       Impact factor: 14.808

6.  Intracellular inflammatory signalling cascades in human monocytic cells on challenge with phytohemagglutinin and 2,4,6-trinitrophenol.

Authors:  N Prajitha; P V Mohanan
Journal:  Mol Cell Biochem       Date:  2021-11-13       Impact factor: 3.396

7.  Patients with inflammatory bowel disease may have a transforming growth factor-beta-, interleukin (IL)-2- or IL-10-deficient state induced by intrinsic neutralizing antibodies.

Authors:  E C Ebert; A Panja; K M Das; R Praveen; X Geng; C Rezac; M Bajpai
Journal:  Clin Exp Immunol       Date:  2009-01       Impact factor: 4.330

Review 8.  Growth control mechanisms in normal and transformed intestinal cells.

Authors:  A W Burgess
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1998-06-29       Impact factor: 6.237

Review 9.  Molecular mechanisms regulating TGF-beta-induced Foxp3 expression.

Authors:  L Xu; A Kitani; W Strober
Journal:  Mucosal Immunol       Date:  2010-03-10       Impact factor: 7.313

Review 10.  CD3 monoclonal antibodies: a first step towards operational immune tolerance in the clinic.

Authors:  Lucienne Chatenoud; Herman Waldmann
Journal:  Rev Diabet Stud       Date:  2012-12-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.